Top Diagnostics Startups in 2027

More than a new kind of dialysis machine, Tablo is a new way of thinking about dialysis and the patients who depend on it. Tablo makes it possible to reconsider where dialysis is performed, when dialysis is performed and who can perform it. Tablo opens up opportunities for new in-center patient-powered care models designed to improve the experience while lowering costs for providers.

Freenome is on a mission to empower everyone with the tools they need to detect, treat, and ultimately prevent diseases. If you crave challenges, understudied problems, and the chance to see your work impact the millions of lives touched by cancer, there’s no better place to be. We are committed to our core values of empathy, integrity, and trust enable us to push through challenges, learn from mistakes, and support one another to reach our fullest potential. By applying advanced ML techniques to recent breakthroughs in genomic science, Freenome is developing simple blood tests to detect early-stage cancer and make treatments more effective. The company has raised $238M from investors such as RA Capital, Polaris Partners, Perceptive Advisors, a16z, funds/accounts advised by T. Rowe Price Associates, Inc., GV (fka Google Ventures), Roche Venture Fund, Kaiser Permanente Ventures, American Cancer Society’s BrightEdge Ventures, Data Collective Venture Capital, & Verily Life Sciences.

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive karius® test that helps clinicians make rapid treatment decisions. our laboratory is clia-certified and cap-accredited to perform high-complexity clinical laboratory testing. we provide unique genomic insights by detecting microbial cell-free dna (mcfdna) circulating in the bloodstream from pathogens causing an acute infection. proprietary technology efficiently extracts mcfdna directly from blood and depletes the strong human background signal and environmental contaminants. advanced machine learning algorithms allow analysis of complex genomic data in real-time. proprietary reference genome databases are constantly refined as more data becomes available.

Tempus is a technology company that has built an operating system to battle cancer. Tempus enables physicians to deliver personalized cancer care through its interactive analytical and machine learning platform. The company provides genomic sequencing services and analyzes molecular and therapeutic data to empower physicians to make real-time, data-driven decisions. Our goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as we gather more data.

We’re defining our place as an essential healthcare service. We’re evolving, but we’re doubling down on our commitment to building a healthier tomorrow, together. At our core, we believe communal well-being is fundamental to individual health. We’ve become attuned to how our communities’ health rests on everyone working together during this pandemic. We’re here to help, wherever you are. We’re building a future where essential health services are accessible to everyone. With the support of scientists, public health officials, and engineers, we’ve designed an infrastructure ready to withstand rapid change. We will continue to provide affordable and science-based services while expanding to reach more communities in need. We imagine new ways to help more people stay healthy, safe, and informed. Our efforts are supported by the optimism and ambition reflected across the U.S.—working together; our potential has no bounds. To learn more about our technology team, check out our careers page: recruitment.curative.com/tech/curative-technology-team

Everly offers convenient, at-home tests ordered by you with easy-to-read results that you can actually understand. Our tests are ordered directly by the customer online, delivered via at-home collection kits, and communicated with completed redesigned lab results. Everly is the only company offering a suite of regulatory-compliant lab tests...without a lab visit. Our first test kits include: cardiovascular, fertility, elements, metabolism, food sensitivity and inflammation. The EverlWell platform is integrated with our lab partners and virtual physician authorization providers, and we've built a custom data translation interface for unstandardized HL7 data.

Altis Labs is the AI-powered computational imaging company advancing precision medicine. Trained on the world's largest cancer imaging database, our deep learning models predict outcomes to quantify treatment effect more accurately. Leading biopharmaceutical companies use our AI platform, Nota, to analyze clinical trial imaging data in a more meaningful way, allowing them to develop effective novel therapies faster. Founded in 2019, Altis is a venture-backed company headquartered in Toronto. We are actively growing our team in Canada and the US across functional areas.

Founded in 2018, we are a group of imaging scientists, engineers, and radiologists aspired to improve healthcare by creating novel medical imaging technology and bringing it to every patient that needs it. Our core technology has its roots at Stanford University, where our founders created the first-ever radiofrequency-penetrable PET insert system for simultaneous PET and MRI imaging. ​Our vision is to make multi-modality medical imaging accessible to every patient. Our mission is to create affordable, high-performance molecular imaging systems that empower doctors to drive early and accurate diagnosis of diseases.

Next generation Point-of-Care Coagulation Viscoelastic Diagnostic CoagCare platform for improved patient outcomes